Strategic Wealth Partners Ltd. Has $10.32 Million Stock Holdings in Becton, Dickinson and Company $BDX

Strategic Wealth Partners Ltd. boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 64.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 68,186 shares of the medical instruments supplier’s stock after acquiring an additional 26,734 shares during the period. Strategic Wealth Partners Ltd.’s holdings in Becton, Dickinson and Company were worth $10,319,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BDX. Auto Owners Insurance Co lifted its position in Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the period. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company during the second quarter worth approximately $3,721,533,000. Wellington Management Group LLP lifted its holdings in Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares during the period. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after buying an additional 4,223,149 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in Becton, Dickinson and Company by 23,219.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after acquiring an additional 4,137,888 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 11,779 shares of company stock worth $1,974,669 over the last ninety days. Company insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on BDX shares. Jefferies Financial Group reiterated a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Barclays raised their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Bank of America reduced their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Trading Up 2.3%

NYSE BDX opened at $191.95 on Friday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $192.30. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The firm has a market cap of $52.89 billion, a P/E ratio of 57.82, a P/E/G ratio of 13.53 and a beta of 0.19. The stock’s 50-day moving average is $161.58 and its 200-day moving average is $161.13.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.Becton, Dickinson and Company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.